- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Stay current with the latest press releases from within the industry.
Amarin Corporation plc Announces Sale of Transdermal Patch Development Unit in Argentina
Release issued 11th December 2001
Amarin Corporation plc (NASDAQ: AMRN) today announced that it has sold its transdermal patch product development business in South America to a group comprised of the Company's local management team. The sale of the transdermal unit to existing management assures a continued commitment to developing this business at the local level. The buyout team will seek to expand their opportunities in transdermal patch and topical product development by utilizing their extensive technology, product development and manufacturing expertise.Company details
If you want to find out more about the company visit Amarin Technologies S.A. profile.
Latest Amarin Technologies S.A. press releases
(12th February 2005) Amarin Technologies SA, announces the approval of its Fentanyl TDS in Argentina.
(5th August 2004) Amarin Technologies Argentina announces a partnership agreement for its Fentanyl patch.
(27th September 2002) Amarin Technologies SA Launches a High Strength Diclofenac Gel
(6th April 2001) Amarin has developed an innovative Diclofenac TDS with systemic effects.
(1st April 2001) Amarin Technologies the New Name for Ethical Pharmaceuticals South America
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us